Researchers at ESTRO 2026 presented evidence that targeted stereotactic body radiotherapy (SBRT) can extend control in early-stage breast cancer that has begun to spread, described as oligometastatic disease. The findings aim to improve progression-free survival for patients with limited metastatic burden. The development is positioned as a potential way to extend disease control while limiting broader systemic escalation, though the presented snapshot emphasizes outcomes within the radiotherapy setting. Clinicians and trial designers may use the data to refine eligibility criteria for who benefits most from targeted local treatment. If supported by follow-up data, the regimen could influence radiotherapy decision pathways for patients caught between localized and widely metastatic stages.